Trial Profile
A Phase 1, Open-label Study of Niraparib as Single Agent in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Niraparib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Takeda
- 30 Apr 2021 Results assessing the safety, tolerability and pharmacokinetics of niraparib in patients with solid tumours, published in the Japanese Journal of Clinical Oncology.
- 13 Oct 2020 Status changed from active, no longer recruiting to completed.
- 29 Oct 2019 Planned End Date changed from 31 Aug 2019 to 30 Sep 2020.